Chen W, Yokoyama M, Kobayashi M, Fan B, Fukuda S, Waseda Y, Tanaka H, Yoshida S, Ai M, Fushimi K, Nonomura N, Fujii Y. Trends of radical cystectomy and comparisons of surgical outcomes among surgical approaches focusing on robot-assisted radical cystectomy: A Japanese nationwide database study Int J Urol. 2022.12;
Yamamoto S, Fukushima H, Fukuda S, Uehara S, Yasuda Y, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Fujii Y. Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab. Asia Pac J Clin Oncol . 2022.08; 18 (4): 410-418.
Matsumoto S, Arita Y, Yoshida S, Fukushima H, Kimura K, Yamada I, Tanaka H, Yagi F, Yokoyama M, Matsuoka Y, Oya M, Tateishi U, Jinzaki M, Fujii Y. Utility of radiomics features of diffusion-weighted magnetic resonance imaging for differentiation of fat-poor angiomyolipoma from clear cell renal cell carcinoma: model development and external validation Abdom Radiol (NY) . 2022.06; 47 (6): 2178-2186.
Matsuoka Y, Uehara S, Toda K, Fukushima H, Tanaka H, Yoshida S, Yokoyama M, Yoshimura R, Kihara K, Fujii Y. Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy Urol Oncol . 2022.04; 40 (4): 161.
Uchida Y, Yoshida S, Arita Y, Shimoda H, Kimura K, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Jinzaki M, Fujii Y. Apparent Diffusion Coefficient Map-Based Texture Analysis for the Differentiation of Chromophobe Renal Cell Carcinoma from Renal Oncocytoma Diagnostics (Basel) (IF: 5.25; Q2). 2022.03;
Yoshida S, Matsushima H, Fujii Y. Classification of oligometastatic prostate cancer with additional consideration for hormone sensitivity World J Urol . 2022.03; 40 (3): 871-873.
Yoshida S, Fujii Y. Editorial Comment from Dr Yoshida and Dr Fujii to Role of Vesical Imaging-Reporting and Data System in predicting muscle-invasive bladder cancer: A diagnostic meta-analysis Int J Urol . 2022.03; 29 (3): 196.
Yoshida S, Takahara T, Arita Y, Toda K, Kimura K, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Fujii Y. Impact of Progressive Site-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer on Subsequent Treatment Response 2022.01; 14 (3): 567.
Kimura K, Yoshida S, Tsuchiya J, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Tateishi U, Fujii Y. Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer Eur Radiol . 2022.01; 32 (1): 671-679.
Fujiwara M, Yokoyama M, Toide M, Fujiwara R, Tanaka H, Oguchi T, Komai Y, Yoshida S, Matsuoka Y, Numao N, Yamamoto S, Fukui I, Yonese J, Fujii Y. Renal function outcome after selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and consolidative partial cystectomy in comparison with radical cystectomy for patients with muscle-invasive bladder cancer: a two-centre retrospective study Jpn J Clin Oncol. 2022;
Tanaka H*, Fukuda S, Kimura K, Fukawa Y, Yamamoto K, Fukushima H, Moriyama S, Yasuda Y, Uehara S, Waseda Y, Yoshida S, Yokoyama M, Matsuoka Y, Saito K, Tateishi U, Campbell SC, Fujii Y. . Defining tumour shape irregularity for preoperative risk stratification of clinically localised renal cell carcinoma Eur Urol Open Sci. . 2022;
Ishikawa Y, Fukushima H, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Sakai Y, Otsuka Y, Takazawa R, Yano M, Tsukamoto T, Okuno T, Noro A, Nagahama K, Kamata S, Fujii Y. Prognostic Accuracy of the qSOFA Score for In-Hospital Mortality in Elderly Patients with Obstructive Acute Pyelonephritis: A Multi-Institutional Study Diagnostics (Basel). 2021.12;
Yokoyama M, Masuda H, Ito M, Waseda Y, Moriyama S, Toide M, Uchida Y, Uehara S, Kijima T, Yoshida S, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Longitudinal changes in patient-reported outcomes after artificial urinary sphincter implantation Low Urin Tract Symptoms. 2020.12;
Kijima T, Yamamoto H, Saito K, Kusuhara S, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Sakai Y, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab Cancer Immunol Immunother. 2020.09;
Kijima T, Fukushima H, Kusuhara S, Tanaka H, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Sakai Y, Saito K, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review Clin Genitourin Cancer. 2020.07;
Nakamura Y, Yokoyama M, Yoshida S, Tanaka H, Kijima T, Ishioka J, Matsuoka Y, Saito K, Minami I, Yoshimoto T, Naito S, Ogawa Y, Yamada T, Uchida S, Fujii Y. Postoperative renal impairment and longitudinal change in renal function after adrenalectomy in patients with Cushing's syndrome Int J Urol. 2020 Mar 11. doi: 10.1111/iju.14205. 2020.03;
Tanaka H, Fukushima H, Kijima T, Nakamura Y, Yajima S, Uehara S, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Feasibility and outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancer Int J Urol. 2020; 27: 236-243. *Equal contribution. 2020;
Kaneko K, Yoshida S, Yamamoto K, Arita Y, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. . Renal epithelioid angiomyolipoma: Incidence in a Japanese cohort and diagnostic utility of diffusion-weighted magnetic resonance imaging. Int J Urol. 2020 Jul;27(7):599-604. doi: 10.1111/iju.14251.. 2020;
Yoshida S, Taniguchi N, Moriyama S, Matsuoka Y, Saito K, Fujii Y. . Application of virtual reality in patient explanation of magnetic resonance imaging-ultrasound fusion prostate biopsy. Int J Urol. 2020; 27: 471-472. doi: 10.1111/iju.14204.. 2020;
Yoshida S, Takahara T, Arita Y, Toda K, Yoshimura R, Fujii Y. . Patterns of failure after progressive site-directed therapy in oligo-progressive castration-resistant prostate cancer. Int J Urol. 2020; 27: 634-635. doi: 10.1111/iju.14249.. 2020;
Matsuoka Y, Uehara S, Yoshida S, Tanaka H, Tanaka H, Kijima T, Yokoyama M, Ishioka J, Saito K, Fujii Y. Value of extra-target prostate biopsy for the detection of magnetic resonance imaging-missed adverse pathology according to the Prostate Imaging Reporting and Data System scores Spatial analysis using magnetic resonance-ultrasound fusion images. Int J Urol. 2020; 27: 760-766. 2020;
Fukushima H, Moriyama S, Waseda Y, Fukuda S, Uehara S, Tanaka H, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Significance of Bladder Neck Involvement in Risk Substratification of Intermediate-Risk Non-muscle-invasive Bladder Cancer Eur Urol Focus. 2020;
Fukushima H, Inoue M, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Incidence and risk factors of hypertension following partial nephrectomy in patients with renal tumors: a cross-sectional study of postoperative home blood pressure and antihypertensive medications Clin Genitourin Cancer. 2020;
Fukushima H, Kijima T, Fukuda S, Moriyama S, Uehara S, Yasuda Y, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Saito K, Matsubara N, Numao N, Sakai Y, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: a preliminary study Cancer Med. 2020; 9: 8355-8363. doi: 10.1002/cam4.3445. 2020;
Fukushima H, Fukuda S, Moriyama S, Uehara S, Yasuda Y, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Fujii Y. Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report Anticancer Drugs. 2020; 31: 866-871. doi: 10.1097/CAD.0000000000000982.. 2020;
Matsuoka Y, Uehara S, Yoshida S, Tanaka H, Yokoyama M, Fujii Y. Three-dimensional analysis of systematic biopsy-derived prostate cancer upgrading over targeted biopsy Int J Urol. 2020 Oct 27. doi: 10.1111/iju.14410. 2020;
SoichiroYoshida1TaroTakahara23ChikakoIshii3YukiArita34YumaWaseda1ToshikiKijima1MinatoYokoyama1JunichiroIshioka1YohMatsuoka1KazutakaSaito1YasuhisaFujii. METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer 2019.12;
Kijima Toshiki, Fukuda Shohei, Fukushima Hiroshi, Moriyama Shingo, Uehara Sho, Yasuda Yosuke, Yoshida Soichiro, Yokoyama Minato, Ishioka Junichiro, Matsuoka Yoh, Saito Kazutaka, Fujii Yasuhisa. Clinical outcomes of muscle-invasive bladder cancer patients with hydronephrosis treated with tetra-modality bladder sparing therapy incorporating consolidative partial cystectomy. JOURNAL OF CLINICAL ONCOLOGY. 2019.03; 37 (7):
Yoshida Soichiro, Fujii Yasuhisa. High cell proliferation as a predictive factor for favorable response to chemoradiotherapy against bladder cancer CANCER SCIENCE. 2018.12; 109 1220.
Yajima Shugo, Yoshida Soichiro, Tanaka Hiroshi, Tanaka Hajime, Inoue Masaharu, Kijima Toshiki, Yokoyama Minato, Ishioka Junichiro, Matsuoka Yoh, Saito Kazutaka, Kihara Kazunori, Fujii Yasuhisa. Predictive significance of absence of inchworm sign on diffusion-weighted MRI for progression of the pT1 bladder cancer INTERNATIONAL JOURNAL OF UROLOGY. 2018.10; 25 234.
Yasuda Yosuke, Saito Kazutaka, Soma Takahiko, Tanaka Hajime, Kijima Toshiki, Yoshida Soichiro, Yokoyama Minato, Ishioka Junichiro, Matsuoka Yoh, Kihara Kazunori, Fujii Yasuhisa. Gasless laparoendoscopic single-port clampless sutureless partial nephrectomy: Perioperative outcomes INTERNATIONAL JOURNAL OF UROLOGY. 2018.10; 25 230.
Saito Kazutaka, Matsuoka Yoh, Yoshida Soichiro, Fujii Yasuhisa. MRI/ultrasound elastic fusion prostate biopsy : application to lesion - specific treatment of local therapy INTERNATIONAL JOURNAL OF UROLOGY. 2018.10; 25 167.
Yoshida Soichiro, Takahara Taro, Ishii Chikako, Nakagawa Keiko, Toda Kazuma, Kijima Toshiki, Yokoyama Minato, Ishioka Junichiro, Matsuoka Yoh, Saito Kazutaka, Yoshimura Ryoichi, Kihara Kazunori, Fujii Yasuhisa. Loco-regional radiotherapy targeting for oligo-progressive CRPC on the diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) INTERNATIONAL JOURNAL OF UROLOGY. 2018.10; 25 358.
Kijima Toshiki, Yoshida Soichiro, Yokoyama Minato, Ishioka Junichiro, Matsuoka Yoh, Saito Kazutaka, Kihara Kazunori, Fujii Yasuhisa. Clinical outcomes of patients with histologic variants of urothelial carcinoma treated with tetra-modality bladder-sparing protocol incorporating consolidative partial cystectomy. JOURNAL OF CLINICAL ONCOLOGY. 2018.02; 36 (6):
吉田 宗一郎. 【Q&Aでまとめる! 予後予測・治療効果予測の画像検査】腎臓・泌尿器・生殖器 去勢抵抗性前立腺癌の予後・治療効果を予測する画像検査法は何か?(Q&A/特集) 臨床放射線. 2020;
吉田 宗一郎. 【これ一冊でパーフェクト!!泌尿器科悪性腫瘍のエビデンス】腎癌 非転移性腎癌 Bosniak III/IVに対する方針 泌尿器外科. 2020;
吉田 宗一郎, 藤井 靖久. . 【オリゴ転移・オリゴ再発前立腺癌を巡る諸問題】去勢抵抗性前立腺癌:oligoprogressive diseaseに対する局所治療 泌尿器外科. 2020;
田中 一, 吉田 宗一郎. 【泌尿器科癌のリンパ節郭清：最新エビデンスとエキスパートの実践】泌尿器科癌リンパ節転移の画像診断 泌尿器外科. 2020;
吉田 宗一郎, 藤井 靖久. 【骨転移の画像診断】骨転移を伴う前立腺癌の臨床と画像診断 臨床画像. 2020;
吉田 宗一郎、藤井 靖久. DWIBS法(ドゥイブス法)を用いた全身拡散強調MRI-概要と泌尿器癌への応用ー 泌尿器外科. 2017.03;
松岡 陽、井上雅晴、伊藤将也、吉田宗一郎、横山みなと、石岡淳一郎、沼尾 昇、齋藤一隆、藤井靖久、木原和徳. 内視鏡操作ロボットを用いたガスレス・シングルポート・ロボサージャン前立腺全摘除 日本ミニマム創泌尿器内視鏡外科学会雑誌. 2016.07; 8 (1): 31-35.
